CY1120457T1 - Αντι-ιικη θεραπεια - Google Patents

Αντι-ιικη θεραπεια

Info

Publication number
CY1120457T1
CY1120457T1 CY20181100548T CY181100548T CY1120457T1 CY 1120457 T1 CY1120457 T1 CY 1120457T1 CY 20181100548 T CY20181100548 T CY 20181100548T CY 181100548 T CY181100548 T CY 181100548T CY 1120457 T1 CY1120457 T1 CY 1120457T1
Authority
CY
Cyprus
Prior art keywords
treatment
cure treatment
hiv
combinations
aids
Prior art date
Application number
CY20181100548T
Other languages
English (en)
Inventor
Mark Richard UNDERWOOD
Original Assignee
Viiv Healthcare Company
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=44319704&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CY1120457(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Viiv Healthcare Company filed Critical Viiv Healthcare Company
Publication of CY1120457T1 publication Critical patent/CY1120457T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/536—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with carbocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Abstract

Η παρούσα εφεύρεση αφορά σε συνδυασμούς ενώσεων που περιλαμβάνουν αναστολείς ιντεγκράσης HIV και άλλους θεραπευτικούς παράγοντες. Τέτοιοι συνδυασμοί είναι χρήσιμοι στην αναστολή αντιγραφής HIV, την πρόληψη ή/και θεραπεία μόλυνσης από HIV και στην θεραπεία AIDS ή/και ARC.
CY20181100548T 2010-01-27 2018-05-23 Αντι-ιικη θεραπεια CY1120457T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US29858910P 2010-01-27 2010-01-27
EP11737484.3A EP2531027B1 (en) 2010-01-27 2011-01-24 Therapeutic combination comprising dolutegravir, abacavir and lamivudine

Publications (1)

Publication Number Publication Date
CY1120457T1 true CY1120457T1 (el) 2019-07-10

Family

ID=44319704

Family Applications (4)

Application Number Title Priority Date Filing Date
CY20151100633T CY1116509T1 (el) 2010-01-27 2015-07-17 Θεραπευτικος συνδυασμος που περιλαμβανει ντολουτεγκραβιρη, αβακαβιρη και λαμιβουδινη
CY20181100548T CY1120457T1 (el) 2010-01-27 2018-05-23 Αντι-ιικη θεραπεια
CY2018029C CY2018029I2 (el) 2010-01-27 2018-10-16 Αντι-ιικη θεραπεια
CY181101087T CY1121040T1 (el) 2010-01-27 2018-10-23 Aντιικη θεραπεια

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CY20151100633T CY1116509T1 (el) 2010-01-27 2015-07-17 Θεραπευτικος συνδυασμος που περιλαμβανει ντολουτεγκραβιρη, αβακαβιρη και λαμιβουδινη

Family Applications After (2)

Application Number Title Priority Date Filing Date
CY2018029C CY2018029I2 (el) 2010-01-27 2018-10-16 Αντι-ιικη θεραπεια
CY181101087T CY1121040T1 (el) 2010-01-27 2018-10-23 Aντιικη θεραπεια

Country Status (45)

Country Link
US (12) US20120295898A1 (el)
EP (6) EP2531027B1 (el)
JP (8) JP2013518107A (el)
KR (4) KR101964923B1 (el)
CN (2) CN105311033B (el)
AP (1) AP3551A (el)
AU (1) AU2011209788C1 (el)
BR (1) BR112012018670A2 (el)
CA (4) CA2967453C (el)
CL (1) CL2012002080A1 (el)
CO (1) CO6602152A2 (el)
CR (1) CR20120423A (el)
CY (4) CY1116509T1 (el)
DK (4) DK2531027T3 (el)
DO (2) DOP2012000205A (el)
EA (4) EA037601B1 (el)
EC (1) ECSP12012106A (el)
ES (3) ES2670811T3 (el)
FI (1) FI3494972T3 (el)
FR (1) FR18C1043I2 (el)
HK (3) HK1250335A1 (el)
HR (3) HRP20150770T1 (el)
HU (4) HUE040554T2 (el)
IL (5) IL221007A (el)
LT (4) LT3127542T (el)
LU (1) LUC00090I2 (el)
MA (1) MA34002B1 (el)
ME (2) ME03058B (el)
MX (4) MX367938B (el)
MY (1) MY188334A (el)
NO (2) NO2932970T3 (el)
NZ (4) NZ627826A (el)
PE (2) PE20160180A1 (el)
PH (2) PH12016500195A1 (el)
PL (3) PL2531027T3 (el)
PT (4) PT3494972T (el)
RS (4) RS54123B1 (el)
SG (3) SG10201707183TA (el)
SI (4) SI2531027T1 (el)
SM (1) SMT201500177B (el)
TN (1) TN2012000376A1 (el)
TR (1) TR201807704T4 (el)
UA (1) UA105556C2 (el)
WO (1) WO2011094150A1 (el)
ZA (1) ZA201205586B (el)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2967453C (en) 2010-01-27 2018-07-17 Viiv Healthcare Company Combinations for use in the inhibition of hiv-1
KR20150084772A (ko) 2012-10-23 2015-07-22 시플라 리미티드 약학 항레트로바이러스 조성물
PT2822954E (pt) 2012-12-21 2016-06-16 Gilead Sciences Inc Compostos carbamoilpiridona policíclicos e seu uso farmacêutico
CA2897137A1 (en) 2013-02-18 2014-08-21 Ratiopharm Gmbh Solid pharmaceutical dosage form of dolutegravir
EP2767272A1 (en) * 2013-02-18 2014-08-20 Ratiopharm GmbH Solid pharmaceutical dosage form of dolutegravir
NO2865735T3 (el) 2013-07-12 2018-07-21
AU2014286993B2 (en) 2013-07-12 2018-10-25 Gilead Sciences, Inc. Polycyclic-carbamoylpyridone compounds and their use for the treatment of HIV infections
AP2016009157A0 (en) 2013-09-27 2016-04-30 Merck Sharp & Dohme Substituted quinolizine derivatives useful as hiv integrase inhibitors
WO2015140569A1 (en) 2014-03-20 2015-09-24 Cipla Limited Pharmaceutical composition
CA2950911C (en) * 2014-06-04 2023-10-10 Sanford-Burnham Medical Research Institute Use of inhibitor of apoptosis protein (iap) antagonists in hiv therapy
NO2717902T3 (el) 2014-06-20 2018-06-23
TW201613936A (en) 2014-06-20 2016-04-16 Gilead Sciences Inc Crystalline forms of(2R,5S,13aR)-8-hydroxy-7,9-dioxo-n-(2,4,6-trifluorobenzyl)-2,3,4,5,7,9,13,13a-octahydro-2,5-methanopyrido[1',2':4,5]pyrazino[2,1-b][1,3]oxazepine-10-carboxamide
TWI744723B (zh) 2014-06-20 2021-11-01 美商基利科學股份有限公司 多環型胺甲醯基吡啶酮化合物之合成
WO2016016279A1 (en) 2014-07-29 2016-02-04 Lek Pharmaceuticals D.D. Novel hydrates of dolutegravir sodium
TWI738321B (zh) 2014-12-23 2021-09-01 美商基利科學股份有限公司 多環胺甲醯基吡啶酮化合物及其醫藥用途
EA201791872A1 (ru) 2015-04-02 2018-04-30 Джилид Сайэнс, Инк. Полициклические карбамоилпиридоновые соединения и их фармацевтическое применение
EP3334419A1 (en) 2015-08-14 2018-06-20 Sandoz AG Solid pharmaceutical composition of abacavir, lamivudine, and efavirenz
WO2017205585A1 (en) * 2016-05-27 2017-11-30 Viiv Healthcare Company Combinations and uses treatments thereof
WO2018028841A1 (en) * 2016-08-12 2018-02-15 Sandoz Ag Solid pharmaceutical composition of abacavir, lamivudine, and efavirenz
WO2018042332A1 (en) * 2016-08-31 2018-03-08 Glaxosmithkline Intellectual Property (No.2) Limited Combinations and uses and treatments thereof
WO2019016679A1 (en) * 2017-07-18 2019-01-24 Viiv Healthcare Company COMBINATION THERAPY
MX2020000790A (es) 2017-07-21 2020-11-11 Viiv Healthcare Co Pautas para el tratamiento de infecciones por el vih y sida.
WO2019016760A1 (en) * 2017-07-21 2019-01-24 Viiv Healthcare Company REGIMES AND PREPARATIONS FOR THE TREATMENT OF HIV INFECTIONS AND AIDS
EP3694522A4 (en) * 2017-10-13 2021-08-04 VIIV Healthcare Company TWO-LAYER PHARMACEUTICAL TABLET FORMULATION
HUE059677T2 (hu) 2019-03-22 2022-12-28 Gilead Sciences Inc Áthidalt triciklusos karbamoilpiridon-vegyületek és ezek gyógyszerészeti alkalmazása
US20230270677A1 (en) * 2020-01-09 2023-08-31 University Of Washington Long-acting therapeutic agent combinations and methods thereof
MX2022009871A (es) 2020-02-24 2022-08-19 Gilead Sciences Inc Compuestos tetraciclicos para tratar la infeccion por el virus de la inmunodeficiencia humana (vih).
KR20230134529A (ko) 2021-01-19 2023-09-21 길리애드 사이언시즈, 인코포레이티드 치환된 피리도트리아진 화합물 및 이의 용도
WO2023164293A1 (en) * 2022-02-28 2023-08-31 Jericho Sciences, Llc Methods for viral infections

Family Cites Families (74)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5047407A (en) 1989-02-08 1991-09-10 Iaf Biochem International, Inc. 2-substituted-5-substituted-1,3-oxathiolanes with antiviral properties
US7119202B1 (en) 1989-02-08 2006-10-10 Glaxo Wellcome Inc. Substituted-1,3-oxathiolanes and substituted-1,3-dioxolanes with antiviral properties
GB8815265D0 (en) 1988-06-27 1988-08-03 Wellcome Found Therapeutic nucleosides
GB9009861D0 (en) 1990-05-02 1990-06-27 Glaxo Group Ltd Chemical compounds
ZA923640B (en) 1991-05-21 1993-02-24 Iaf Biochem Int Processes for the diastereoselective synthesis of nucleosides
GB9111902D0 (en) 1991-06-03 1991-07-24 Glaxo Group Ltd Chemical compounds
GB9204015D0 (en) 1992-02-25 1992-04-08 Wellcome Found Therapeutic nucleosides
IL106507A (en) 1992-08-07 1997-11-20 Merck & Co Inc Pharmaceutical compositions containing benzoxazinones and some novel compounds of this type
US5519021A (en) 1992-08-07 1996-05-21 Merck & Co., Inc. Benzoxazinones as inhibitors of HIV reverse transcriptase
GB9402161D0 (en) 1994-02-04 1994-03-30 Wellcome Found Chloropyrimidine intermediates
IL113432A (en) 1994-04-23 2000-11-21 Glaxo Group Ltd Process for the diastereoselective synthesis of nucleoside analogues
UA49803C2 (uk) 1994-06-03 2002-10-15 Дж.Д. Сьорль Енд Ко Спосіб лікування ретровірусних інфекцій
MY115461A (en) 1995-03-30 2003-06-30 Wellcome Found Synergistic combinations of zidovudine, 1592u89 and 3tc
US5914332A (en) 1995-12-13 1999-06-22 Abbott Laboratories Retroviral protease inhibiting compounds
US5849911A (en) 1996-04-22 1998-12-15 Novartis Finance Corporation Antivirally active heterocyclic azahexane derivatives
CN1228026A (zh) * 1996-06-25 1999-09-08 葛兰素集团有限公司 用于治疗hiv感染的含有vx478、叠氮胸苷、ftc和/或3tc的复方制剂
US5922695A (en) 1996-07-26 1999-07-13 Gilead Sciences, Inc. Antiviral phosphonomethyoxy nucleotide analogs having increased oral bioavarilability
US5965729A (en) 1997-02-05 1999-10-12 Merck & Co., Inc. Process for the crystallization of a reverse transcriptase inhibitor using an anti-solvent
GB9709945D0 (en) 1997-05-17 1997-07-09 Glaxo Group Ltd A novel salt
US5935946A (en) 1997-07-25 1999-08-10 Gilead Sciences, Inc. Nucleotide analog composition and synthesis method
GB9717928D0 (en) 1997-08-22 1997-10-29 Glaxo Group Ltd Process for the enatioselective hydrolysis of n-derivatised lactams
GB9721780D0 (en) 1997-10-14 1997-12-10 Glaxo Group Ltd Process for the synthesis of chloropurine intermediates
US6436989B1 (en) 1997-12-24 2002-08-20 Vertex Pharmaceuticals, Incorporated Prodrugs of aspartyl protease inhibitors
US6087383A (en) 1998-01-20 2000-07-11 Bristol-Myers Squibb Company Bisulfate salt of HIV protease inhibitor
GB9805898D0 (en) 1998-03-20 1998-05-13 Glaxo Group Ltd Process for the sythesis of hiv protease inhibitors
EP1063888A1 (en) 1998-03-27 2001-01-03 The Regents of the University of California Novel hiv integrase inhibitors and hiv therapy based on drug combinations including integrase inhibitors
UA72207C2 (uk) 1998-04-07 2005-02-15 Брістол- Майєрс Сквібб Фарма Компані Фармацевтична композиція ефавіренцу з добавкою дезінтегруючих агентів у вигляді швидкорозчинних капсул або таблеток та спосіб її виготовлення
GB9809213D0 (en) * 1998-04-29 1998-07-01 Glaxo Group Ltd Pharmaceutical compositions
GB9815567D0 (en) 1998-07-18 1998-09-16 Glaxo Group Ltd Antiviral compound
ES2286097T7 (es) 2000-01-31 2009-11-05 Cook Biotech, Inc Valvulas de endoprotesis.
AU2002242926B2 (en) 2001-04-10 2007-10-11 Pfizer Inc. Pyrazole derivatives for treating HIV
JO3429B1 (ar) * 2001-08-13 2019-10-20 Janssen Pharmaceutica Nv مشتقات برميدينات مثبطة فيروس الايدز
US7638522B2 (en) * 2001-08-13 2009-12-29 Janssen Pharmaceutica N.V. Salt of 4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethylphenyl]amino]-2-pyrimidinyl]amino] benzonitrile
MY169670A (en) 2003-09-03 2019-05-08 Tibotec Pharm Ltd Combinations of a pyrimidine containing nnrti with rt inhibitors
TW200403061A (en) * 2002-06-04 2004-03-01 Glaxo Group Ltd Pharmaceutical compositions
DE60303131T2 (de) 2002-06-27 2006-07-20 Medivir Ab Synergistische wechselwirkung von abacavir und alovudin
JP4996241B2 (ja) * 2003-01-14 2012-08-08 ギリアード サイエンシーズ， インコーポレイテッド 組み合わせ抗ウイルス治療のための組成物および方法
TW200510425A (en) 2003-08-13 2005-03-16 Japan Tobacco Inc Nitrogen-containing fused ring compound and use thereof as HIV integrase inhibitor
MXPA06009132A (es) * 2004-02-11 2007-03-26 Smithkline Beecham Corp Inhibidores de integrasa de vih.
ATE411030T1 (de) * 2004-04-14 2008-10-15 Gilead Sciences Inc Phosphonatanaloga von hiv- integrasehemmerverbindungen
EP2332538A1 (en) * 2004-05-21 2011-06-15 Japan Tobacco, Inc. Combinations comprising a 4-isoquinolone derivative and anti-HIV agents
US7176196B2 (en) 2004-05-28 2007-02-13 Bristol-Myers Squibb Company Bicyclic heterocycles as HIV integrase inhibitors
JP4559431B2 (ja) 2004-08-23 2010-10-06 テバ ファーマシューティカル インダストリーズ リミティド 固体及び結晶イバンドロネートナトリウム及びその調製方法
AU2005279158C1 (en) 2004-09-02 2010-12-16 Janssen Pharmaceutica N.V. Hydrochloride of 4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethylphenyl]amino]-2-pyrimidinyl] amino]benzonitrile
ATE414092T1 (de) 2004-09-17 2008-11-15 Idenix Pharmaceuticals Inc Phosphoindole als hiv-inhibitoren
WO2006096444A2 (en) 2005-03-04 2006-09-14 Smithkline Beecham Corporation Chemical compounds
UA96568C2 (en) * 2005-04-28 2011-11-25 Глаксосмиткляйн Ллк Polycyclic carbamoyl pyridone derivative as hiv-integrase inhibitor
PT3372281T (pt) * 2005-04-28 2021-10-14 Shionogi & Co Derivado policíclico de carbamoilpiridona possuindo atividade inibidora de hiv-integrase
CN101336107A (zh) * 2005-12-30 2008-12-31 吉里德科学公司 改善hiv整合酶抑制剂的药物动力学的方法
AU2006332664B2 (en) 2005-12-30 2013-03-14 Gilead Sciences, Inc. Methods for improving the pharmacokinetics of HIV integrase inhibitors
SI1981506T1 (sl) * 2006-01-20 2013-08-30 Janssen R&D Ireland Dolgoročno zdravljenje infekcije HIV s TCM278
US20080039428A1 (en) 2006-06-29 2008-02-14 Panacos Pharmaceuticals, Inc. Antiretroviral combination therapy
CA2657936C (en) 2006-07-21 2017-01-10 Gilead Sciences, Inc. Antiviral protease inhibitors
MX2009003410A (es) 2006-09-29 2009-07-17 Idenix Pharmaceuticals Inc Fosfoindoles enantiomericamente puros como inhibidores de vih.
US20080241289A1 (en) 2007-02-23 2008-10-02 Auspex Pharmaceuticals, Inc. Preparation and utility of non-nucleoside reverse transcriptase inhibitors
ES2779826T3 (es) 2007-02-23 2020-08-20 Gilead Sciences Inc Moduladores de propiedades farmacocinéticas de agentes terapéuticos
KR20100041798A (ko) 2007-06-29 2010-04-22 한국화학연구원 신규 ｈｉｖ 역전사효소 억제제
JP2010532350A (ja) 2007-06-29 2010-10-07 コレア リサーチ インスティテュート オブ ケミカル テクノロジー 新規のｈｉｖ逆転写酵素阻害剤
KR20100040896A (ko) 2007-07-06 2010-04-21 길리애드 사이언시즈, 인코포레이티드 치료제의 약동학적 특성의 조절제
RU2498979C2 (ru) 2007-07-12 2013-11-20 Тиботек Фармасьютикалз Кристаллическая форма 4-[[4-[[4-(2-цианоэтенил)-2,6-диметилфенил]амино]-2-пиримидинил]амино]бензонитрила
WO2009058923A1 (en) 2007-10-31 2009-05-07 Smithkline Beecham Corporation Ccr5 antagonists as therapeutic agents
EP2217573A4 (en) 2007-11-01 2011-08-31 Uab Research Foundation TREATMENT AND PREVENTION OF VIRUS INFECTIONS
US8108055B2 (en) 2007-12-28 2012-01-31 Larry Wong Method, system and apparatus for controlling an electrical device
WO2009082819A1 (en) * 2008-01-03 2009-07-09 Virochem Pharma Inc. Novel lupane derivatives
WO2009082818A1 (en) 2008-01-03 2009-07-09 Virochem Pharma Inc. Novel c-21-keto lupane derivatives preparation and use thereof
JP5629585B2 (ja) 2008-01-04 2014-11-19 ギリアード サイエンシーズ， インコーポレイテッド シトクロムｐ４５０のインヒビター
CA2714049A1 (en) 2008-02-14 2009-08-20 Virochem Pharma Inc. Novel 17.beta. lupane derivatives
WO2009148600A2 (en) * 2008-06-06 2009-12-10 Concert Pharmaceuticals, Inc. Deuterated lysine-based compounds
ES2448766T3 (es) * 2008-07-25 2014-03-17 Viiv Healthcare Company Profármacos de dolutegravir
CA2955957A1 (en) * 2008-12-11 2010-06-17 Shionogi & Co., Ltd. Synthesis of carbamoylpyridone hiv integrase inhibitors and intermediates
CN106986823A (zh) 2008-12-11 2017-07-28 盐野义制药株式会社 氨甲酰基吡啶酮hiv整合酶抑制剂的方法和中间体
CA2967453C (en) 2010-01-27 2018-07-17 Viiv Healthcare Company Combinations for use in the inhibition of hiv-1
GB201006038D0 (en) 2010-04-12 2010-05-26 Unilever Plc Improvements relating to antiviral compositions
EP2590971A4 (en) 2010-06-17 2014-12-10 Fuzians Biomedicals Inc COMPOUNDS USEFUL AS ANTIVIRAL AGENTS, COMPOSITIONS, AND METHODS OF USE

Also Published As

Publication number Publication date
HUS1800042I1 (hu) 2018-11-28
KR101964923B1 (ko) 2019-04-02
IL257267A (en) 2018-03-29
EP3127542A1 (en) 2017-02-08
US20170216284A1 (en) 2017-08-03
PL2531027T3 (pl) 2016-01-29
NO2932970T3 (el) 2018-08-18
FR18C1043I1 (el) 2018-11-30
IL281959B (en) 2021-12-01
IL221007A0 (en) 2012-09-24
RS57728B1 (sr) 2018-12-31
JP2019167371A (ja) 2019-10-03
HUE026849T2 (en) 2016-08-29
KR101830715B1 (ko) 2018-04-04
PH12016500195B1 (en) 2016-12-05
JP2023085431A (ja) 2023-06-20
EA201690872A3 (ru) 2016-12-30
HRP20180855T1 (hr) 2018-06-29
US20170079982A1 (en) 2017-03-23
UA105556C2 (uk) 2014-05-26
EA201892277A1 (ru) 2019-03-29
RS65183B1 (sr) 2024-03-29
CA3060290A1 (en) 2011-08-04
ME02182B (me) 2015-10-20
IL245182B (en) 2018-04-30
HK1250335A1 (zh) 2018-12-14
CN105311033B (zh) 2019-05-07
PT3494972T (pt) 2024-02-12
PL3127542T3 (pl) 2019-03-29
NZ627826A (en) 2016-01-29
US20150238496A1 (en) 2015-08-27
HUE037812T2 (hu) 2018-09-28
AP3551A (en) 2016-01-18
SI3127542T1 (sl) 2018-11-30
JP2016145204A (ja) 2016-08-12
NZ601319A (en) 2014-08-29
EA202190473A2 (ru) 2021-06-30
IL257267B (en) 2019-08-29
RS54123B1 (en) 2015-12-31
FR18C1043I2 (fr) 2019-10-11
AU2011209788A1 (en) 2012-08-16
EP2531027B1 (en) 2015-05-06
EA025176B1 (ru) 2016-11-30
ZA201205586B (en) 2014-01-29
CA2787691C (en) 2018-07-17
US20210401850A1 (en) 2021-12-30
EP3351249A1 (en) 2018-07-25
KR20170078868A (ko) 2017-07-07
MX367938B (es) 2019-09-12
US20180200254A1 (en) 2018-07-19
CA2787691A1 (en) 2011-08-04
CY2018029I1 (el) 2019-07-10
EA032868B1 (ru) 2019-07-31
AU2011209788B2 (en) 2014-02-06
EP3494972B1 (en) 2023-12-13
EA202190473A3 (ru) 2021-12-31
EP2932970A1 (en) 2015-10-21
DK3127542T3 (en) 2018-11-12
HRP20150770T1 (hr) 2015-08-28
HRP20181531T1 (hr) 2018-11-16
BR112012018670A2 (pt) 2018-02-06
CY1116509T1 (el) 2017-03-15
PH12018502489A1 (en) 2020-06-15
AU2011209788C1 (en) 2014-08-28
LUC00090I2 (el) 2019-01-08
SI2531027T1 (sl) 2015-08-31
US20200230147A1 (en) 2020-07-23
EP4316599A2 (en) 2024-02-07
PT2531027E (pt) 2015-09-16
WO2011094150A1 (en) 2011-08-04
PT2932970T (pt) 2018-06-08
US20160339033A1 (en) 2016-11-24
EA037601B1 (ru) 2021-04-20
NZ627824A (en) 2016-02-26
EP2531027A4 (en) 2013-07-03
NO2018036I1 (no) 2018-10-15
US20160199379A1 (en) 2016-07-14
SMT201500177B (it) 2015-09-07
ECSP12012106A (es) 2013-05-31
MY188334A (en) 2021-11-30
LT3127542T (lt) 2018-11-26
EA201690872A2 (ru) 2016-08-31
JP2017008087A (ja) 2017-01-12
AP2012006445A0 (en) 2012-08-31
CA3060290C (en) 2022-07-12
TR201807704T4 (tr) 2018-06-21
IL267658A (en) 2019-08-29
JP2018127473A (ja) 2018-08-16
CA2967453C (en) 2018-07-17
MA34002B1 (fr) 2013-02-01
TN2012000376A1 (en) 2014-01-30
SG10201509476RA (en) 2015-12-30
CN102791129A (zh) 2012-11-21
SG10201707183TA (en) 2017-10-30
PE20121524A1 (es) 2012-12-03
ME03058B (me) 2019-01-20
LT3494972T (lt) 2024-03-12
DK3494972T3 (da) 2024-01-29
ES2543066T3 (es) 2015-08-14
KR20180078358A (ko) 2018-07-09
US20180098992A1 (en) 2018-04-12
DK2531027T3 (en) 2015-07-20
DOP2021000147A (es) 2022-01-16
ES2688925T3 (es) 2018-11-07
CA2967453A1 (en) 2011-08-04
EP3494972A1 (en) 2019-06-12
LTPA2018013I1 (lt) 2018-11-12
IL221007A (en) 2016-06-30
IL245182A0 (en) 2016-06-30
EP3127542B1 (en) 2018-08-22
PH12016500195A1 (en) 2016-12-05
CN102791129B (zh) 2015-09-30
US11234985B2 (en) 2022-02-01
US20170119777A1 (en) 2017-05-04
CN105311033A (zh) 2016-02-10
PE20160180A1 (es) 2016-05-04
JP2013518107A (ja) 2013-05-20
EP2531027A1 (en) 2012-12-12
US20170281636A1 (en) 2017-10-05
KR20160111536A (ko) 2016-09-26
CA3003988C (en) 2020-01-07
DOP2012000205A (es) 2012-10-15
US10426780B2 (en) 2019-10-01
HUE040554T2 (hu) 2019-03-28
PL2932970T3 (pl) 2018-08-31
NZ627827A (en) 2016-02-26
IL267658B (en) 2021-04-29
PT3127542T (pt) 2018-11-26
CL2012002080A1 (es) 2012-11-30
JP2021091705A (ja) 2021-06-17
HK1209629A1 (en) 2016-04-08
IL281959A (en) 2021-05-31
SI2932970T1 (en) 2018-07-31
MX356891B (es) 2018-06-19
DK2932970T3 (en) 2018-05-28
CO6602152A2 (es) 2013-01-18
EP4316599A3 (en) 2024-04-10
LT2932970T (lt) 2018-06-25
CY2018029I2 (el) 2019-07-10
LTC2932970I2 (lt) 2022-04-25
MX367937B (es) 2019-09-12
RS57323B1 (sr) 2018-08-31
SG182614A1 (en) 2012-08-30
MX2012008774A (es) 2012-08-17
CA3003988A1 (en) 2011-08-04
FI3494972T3 (fi) 2024-03-01
SI3494972T1 (sl) 2024-03-29
EP2932970B1 (en) 2018-03-21
CY1121040T1 (el) 2019-12-11
US20120295898A1 (en) 2012-11-22
KR101883750B1 (ko) 2018-07-31
KR20120128640A (ko) 2012-11-27
ES2670811T3 (es) 2018-06-01
JP6268386B2 (ja) 2018-01-31
EA201290583A1 (ru) 2013-04-30
HK1179522A1 (en) 2013-10-04
CR20120423A (es) 2012-11-22
JP2022071126A (ja) 2022-05-13

Similar Documents

Publication Publication Date Title
CY1120457T1 (el) Αντι-ιικη θεραπεια
CY1122186T1 (el) Μεθοδοι θεραπειας καρκινου
CY1123810T1 (el) Τριφθορομεθυλ υποκατεστημενα πυραζολια ως αναστολεις καλλικρεϊνης στο ανθρωπινο πλασμα
CY1124928T1 (el) Αναστολεις πυραζολυλο κινοξαλινο κινασης
CY1124311T1 (el) Παρεμποδιστες dna-pk
CY1114981T1 (el) Προφαρμακα ντολουτεγκραβιρης
EA201200631A1 (ru) Ингибиторы репликации вируса иммунодефицита человека
CY1118774T1 (el) Φαρμακευτικη συνθεση η οποια περιλαμβανει εναν μη νουκλεοσιδικο αναστολεα αναστροφης μεταγραφασης
ECSP109889A (es) Composiciones terapeuticas y usos de las mismas
EA201391395A1 (ru) Терапевтические соединения
EA201390609A1 (ru) ПРОИЗВОДНЫЕ ГИДАНТОИНА, ПОЛЕЗНЫЕ В КАЧЕСТВЕ ИНГИБИТОРОВ Kv3-КАНАЛОВ
EA200901490A1 (ru) Химические соединения
EA201500383A1 (ru) Производные 1,2,4-триазина для лечения вирусных инфекций
CY1121999T1 (el) Φαρμακοτεχνικες μορφες συνδυασμου δαρουναβιρης
EA201390428A1 (ru) Композиции и способы лечения легочной гипертензии
CY1121334T1 (el) Αναστολεας κινασης aurora a
HN2012000023A (es) Compuestos y composiciones para el tratamiento de enfermedades parasitarias
CY1124907T1 (el) Αναστολεις καλλικρεϊνης στο ανθρωπινο πλασμα
CY1116234T1 (el) Υποκατεστημενα 2-οξυ-κινολινο-3-καρβοξαμιδια σαν διαμορφωτες kcnq2/3
CY1116158T1 (el) Υποκατεστημενα 2-οξο- και 2-θειοξο-διυδροκινολινο-3-καρβοξαμιδια σαν διαμορφωτες kcnq2/3
CY1118920T1 (el) Ενωσεις πιπεραζινης- πιπεριδινης ως αναστολεις του ιου ηπατιτιδας c
EA201790020A1 (ru) Соединения, фармацевтические композиции и их применение при лечении нейродегенеративных заболеваний
CY1118255T1 (el) Υποκατεστημενα 6-αμινο-νικοτιναμιδια τα οποια φερουν μια ομαδα που περιεχει οη ως διαμορφωτες των kcnq2/3
CY1118804T1 (el) Αναστολεις πυραζολυλο κινοξαλινο κινασης
CY1115356T1 (el) Συντηγμeνες ιμιδαζολες και συνθεσεις περιλαμβανοντας αυτες για την αγωγη παρασιτικων παθησεων, οπως ειναι π.χ. η ελονοσια